FDA Will Accept Behind-The-Counter NDAs While Mulling “Continuum” Class
This article was originally published in The Tan Sheet
Executive Summary
FDA is open to behind-the-counter switch applications in which companies propose innovative methods to solve access or selection issues, according to Office of Nonprescription Products staff